Blood test could help improve prostate cancer outcomes
ConclusionAbiraterone is an expensive drug, which can work well in some men, but not in others. NICE is yet to make a decision on whether it can be widely used on the NHS because of cost concerns. The cost would be far more palatable if it was possible to tell in advance which men would benefit from using the drug.This is an early-stage study that establishes an apparent relationship between certain gene mutations detectable on blood tests and the chances of a man benefiting from abiraterone after his cancer has progressed and is no longer responding to first treatments.The results need to be confirmed in larger studies. The researchers suggest prospective clinical trials, in which men are selected for treatment on the basis of their test results, to see if this strategy helps men get the treatment most suitable for their tumour. This would be a big step towards "personalised medicine" for prostate cancer, in which treatments can be targeted at those most likely to benefit.However, we do need to be cautious. Only 17 of the men had a complete response to abiraterone, and many who had no gene mutations related to androgen receptors either had a small response, or no response to treatment. The study seems to identify a group who are less likely to benefit from treatment, but it does not follow that everyone who isn't in that group will benefit. We also don't know the effect of treating men who do have gene mutations with other types of treatment. It may be that th...
ConclusionsThe EAU Prostate Cancer Centre Consensus Meeting defined the criteria for the identification of the EPCCE in the fields of clinics, research, and education. The inclusion of a quality control approach represents the novelty that supports the excellence of these centres.Patient summaryA task force of experts defined the criteria for the identification of European Prostate Cancer Centres of Excellence, in order to certify the high-quality centres for prostate cancer management.
Publication date: Available online 22 February 2019Source: European UrologyAuthor(s): John R. Prensner, Felix Y. Feng
ConclusionsThese results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.
ConclusionsThe volume of the bladder wall decreased during IMRT. The range of subtraction of the volume of the bladder wall was extensive. Thus, the estimation of the bladder wall may be useful to reduce the inter-fraction variation.
The objective of this compound is to decrease the rate of rectal toxicity related to radiation therapy, by creating a gap between the prostate and rectum. Secondary benefits include decreased urinary complications and improved sexual quality of life. The hydrogel spacer maintains space for approximately 3 months, and is absorbed in about 6 months.
To evaluate the efficacy and clinical impact of 3 Tesla in-bore trans-rectal magnetic resonance-guided biopsy (3T MRGB) for prostate cancer (PCa) detection based on PIRADSv2 in patients with either suspected prostate cancer or under active surveillance.
We describe our experience using MRI fused CBCT guidance for prostate biopsy. There are no published reports on the use of CBCT guidance in prostate biopsies. We hypothesize this technique will have an adequate safety profile while accurately detecting prostate cancer.
To retrospectively evaluate PAE for palliation of symptoms in prostate cancer (PCa) patients who are non-surgical candidates.
Theranostic drugs under development for prostate cancer (PCa) must be tested in a large animal model prior to human clinical trials. We developed an orthotopic PCa model in dogs to target the gastrin-releasing peptide receptor (GRPR). Prostate cancer in men markedly overexpresses GRPR compared to normal or hyperplastic prostate.
Transrectal focal laser ablation (FLA) of prostate cancer in the MRI environment carries with it the risk of thermal damage to the rectal wall resulting in rectourethral fistula (RUF) formation with painful and/or prolonged cystoprostatitis. RUF ’s are treated surgically with temporary colonic diversion (colostomy) and flap interposition between the rectum and urethra which leaves the patient lifestyle limitations and often urinary incontinence. An alternative treatment for small RUF’s is a conservative medical course including weeks of urinary catheterization.